Sugi Predict

Sugi Predict / Compounds / SCHEMBL3115202

SCHEMBL3115202

SCHEMBL3115202

COCCN1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 1/20 0.55
▸ CTSK P43235 2/20 0.50
▸ DRD2 P14416 6/20 0.46
▸ CCR5 P51681 1/20 0.46
▸ DRD3 P35462 2/20 0.46
▸ BTK Q06187 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ HTR4 Q13639 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HSD11B1 P28845 1/20 0.43
▸ ACKR3 P25106 1/20 0.42
▸ EPHX1 P07099 2/20 0.42
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18609563 0.92 KCNA3 (0.51) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL28840007 0.92 KCNA3 (0.53) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL31350969 0.92 CTSK (0.54) KCNA3CTSKDRD2CCR5BTK
SCHEMBL4760794 0.92 CTSK (0.54) KCNA3CTSKDRD2CCR5BTK
SCHEMBL27345499 0.92 CTSK (0.54) KCNA3CTSKDRD2CCR5BTK
SCHEMBL12788369 0.89 KCNA3 (0.55) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL2672075 0.86 KCNA3 (0.47) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL2822899 0.86 KCNA3 (0.53) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL13612905 0.86 KCNA3 (0.53) KCNA3CTSKDRD2CCR5DRD3
SCHEMBL20519467 0.85 CTSK (0.46) KCNA3CTSKDRD2CCR5DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-10-10 — — US disclosed
EP-4209485-A1 COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2023-07-12 — — EP disclosed
EP-4209485-A1 COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2023-07-12 — — EP disclosed
WO-2022048631-A1 COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF 上海翊石医药科技有限公司 2022-03-10 — — WO disclosed
US-8524709-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2013-09-03 — — US disclosed
US-8524709-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2013-09-03 — — US disclosed
US-20120115866-A1 KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. (US) 2012-05-10 — — US disclosed
US-20120115866-A1 KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. (US) 2012-05-10 — — US disclosed
US-8039470-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2011-10-18 — — US disclosed
US-8039470-B2 Kinase inhibitor compounds TYROGENEX, INC. (US) 2011-10-18 — — US disclosed
US-7626031-B2 5-[(1-Ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; antiproliferative agents; modulating cell differentiation,migration, and chemoinvasion; endothelial growth factor-modulated diseases; antiarthritic agents; graft versus host diseases SYMPHONY EVOLUTION, INC. (US) 2009-12-01 — — US disclosed
US-7626031-B2 5-[(1-Ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; antiproliferative agents; modulating cell differentiation,migration, and chemoinvasion; endothelial growth factor-modulated diseases; antiarthritic agents; graft versus host diseases SYMPHONY EVOLUTION, INC. (US) 2009-12-01 — — US disclosed
US-20090076005-A1 Kinase inhibitor compounds XCOVERY, INC. (US) 2009-03-19 — — US disclosed
EP-2001880-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2008-12-17 — — EP disclosed
US-7452906-B2 Pyridine derivatives as Raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2008-11-18 — — US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 — — US disclosed
WO-2007103308-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-09-13 — — WO disclosed
EP-1423384-B1 PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2007-05-23 — — EP disclosed
EP-1423384-A1 PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2004-06-02 — — EP disclosed
WO-2003022840-A1 PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076005-A1 Kinase inhibitor compounds MAP3K1, MAP3K20, MAP3K2 KCNA3 2940/4885CTSK 571/4885DRD2 4780/4885
US-20120115866-A1 KINASE INHIBITOR COMPOUNDS MAP3K1, MAP3K20, MAP3K2 KCNA3 2940/4885CTSK 571/4885DRD2 4780/4885
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof PRMT5, PRMT1, PRMT6 KCNA3 4533/4885CTSK 4219/4885DRD2 4482/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 KCNA3 2753/4885CTSK 1544/4885DRD2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.